OnKure Therapeutics (OKUR) Cash & Equivalents (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Cash & Equivalents data on file, last reported at $192.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 98.66% year-over-year to $192.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.1 million (up 98.66% YoY) and the FY2025 annual result came in at $59.0 million, down 46.69% from the prior year.
• Cash & Equivalents rose to $192.1 million in Q1 2026, from $59.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $192.1 million in Q1 2026 to a low of $9.1 million in Q2 2023.
• A 5-year average of $67.5 million and a median of $62.1 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 92.32% — and 2024, when it soared 553.49%.
• Tracing OKUR's Cash & Equivalents over 5 years: stood at $19.9 million in 2022, then soared by 50.05% to $29.9 million in 2023, then soared by 270.44% to $110.8 million in 2024, then sank by 46.69% to $59.0 million in 2025, then soared by 225.32% to $192.1 million in 2026.
• The last three Cash & Equivalents figures came in at $192.1 million (Q1 2026), $59.0 million (Q4 2025), and $70.3 million (Q3 2025), per Business Quant data.